Aqilion receives regulatory approval to conduct Phase 1 clinical trial in Regulus program within inflammatory diseases

Aqilion is announcing today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has approved the company’s Phase 1 clinical trial with its drug candidate AQ280. Aqilion applied to conduct a Phase I safety study in 64 healthy volunteers with the drug candidate AQ280 within the Regulus program. The study, ARIA-1, will be conducted in the UK. The purpose of the study is to investigate possible side effects and pharmacokinetics (how the body breaks down and gets rid of the substance). The study will be conducted as a dose escalation study by beginning with a very